PFE's non-oncology portfolio draws focus in Q2, with strength in Vyndaqel and Nurtec offsetting some vaccine softness.

The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2025 of $0.22 per Class A ordinary share.

Strengthens Board of Directors with appointment of two new independent members, increasing independent representation to greater than 90%Underscores Royalty Pharma’s commitment to enhanced corporate ...

ORG Partners LLC trimmed its stake in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 93.3% during the first quarter, Holdings Channel.com reports. The firm owned 3,420 shares of the ...

The pharmaceutical giant Pfizer will pay nearly $60 million to resolve charges that a company it acquired paid kickbacks so that physicians would prescribe a specific migraine drug to patients.

Pfizer Inc. (NYSE:PFE) specializes in biopharmaceutical products. It offers medicines and vaccines. For cardiovascular and migraine, it has the Eliquis, Nurtec ODT/Vydura, Zavzpret, and Premarin ...

Although the company will lose patent exclusivity for several top drugs, it also has newer products on the market, such as cancer therapies Adcetris and Padcev along with migraine drug Nurtec ODT ...

More recently, Pfizer agreed to pay nearly $60 million in 2025 for fraudulent marketing of Nurtec ODT. The company is also facing lawsuits in Canada over its COVID-19 vaccine, including one from an ...